Abstract: 2-Deoxy-D-glucose (2-DG) is a synthetic, non-metabolizable glucose analog that has garnered significant attention in cancer metabolism and oncology. By exploiting the Warburg effect—the propensity of cancer cells to rely on aerobic glycolysis for energy—2-DG competitively inhibits key glycolytic enzymes, leading to severe ATP depletion. Beyond energy disruption, 2-DG interferes with N-linked glycosylation, triggering endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), and blocks the pentose phosphate pathway (PPP), thereby exacerbating oxidative stress. Despite its potent in vitro and in vivo anticancer activities, the clinical translation of 2-DG has been hindered by its poor pharmacokinetic profile, dose-limiting toxicities (such as hypoglycemia and cardiotoxicity), and the metabolic flexibility of tumors under normoxic conditions. Recent advancements in structure-activity relationship (SAR) studies have led to the development of halogenated analogs and lipophilic prodrugs (e.g., WP1122) that aim to overcome these limitations. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, SAR, limitations, and future therapeutic perspectives of 2-DG in oncology.
1. Introduction
A major hallmark of cancer is the reprogramming of cellular metabolism to sustain rapid proliferation and survival. Unlike normal cells that rely primarily on oxidative phosphorylation (OXPHOS) in the presence of oxygen, cancer cells preferentially utilize glycolysis to generate adenosine triphosphate (ATP) and metabolic intermediates, a phenomenon known as the Warburg effect [2][3]. To meet their vast energy demands, tumor cells upregulate glucose transporters (GLUTs) and glycolytic enzymes, resulting in enhanced glucose uptake [2][6]. This metabolic vulnerability provides a compelling rationale for the development of glycolytic inhibitors as anticancer agents.
2-Deoxy-D-glucose (2-DG) is a synthetic glucose analog in which the hydroxyl group at the C-2 position is replaced by a hydrogen atom [2]. Due to its structural similarity to glucose, 2-DG is readily taken up by cancer cells via GLUT transporters and acts as a competitive inhibitor of glucose metabolism [1][8]. While initially investigated as a monotherapy in the 1950s, modern oncological research focuses on 2-DG as a multifaceted metabolic disruptor capable of inducing energy crisis, oxidative stress, and apoptosis in various malignancies [3].
2. Pharmacological Activity
2-DG exhibits broad-spectrum anticancer activity by influencing bioenergetics, cellular proliferation, and survival pathways. In vitro studies demonstrate that 2-DG reduces cell viability, inhibits clonogenic survival, and promotes apoptosis in numerous cancer models, including breast, prostate, and mesothelioma cell lines [1][2]. Interestingly, 2-DG has been shown to upregulate the expression of GLUT1, thereby increasing its own cellular uptake [1]. Furthermore, 2-DG exerts antiangiogenic effects at concentrations that primarily affect endothelial cells without directly influencing tumor cell viability [1].
A significant pharmacological attribute of 2-DG is its ability to act as a potent chemo- and radiosensitizer. It synergistically enhances the efficacy of standard-of-care therapies, including paclitaxel, docetaxel, cisplatin, pemetrexed, and sorafenib, by lowering the apoptotic threshold of resistant cancer cells [1][2]. In vivo, chronic dietary administration of 2-DG has been shown to inhibit the growth of implanted tumors, such as Ehrlich's ascites tumor in mice [7].
3. Molecular Mechanism of Action
The cytotoxicity of 2-DG is mediated through a hierarchy of mechanisms depending on the dose and the oxygenation status of the tumor microenvironment [2].
Inhibition of Glycolysis and Energy Depletion: Upon entering the cell, 2-DG is phosphorylated by hexokinase (HK) to form 2-deoxy-D-glucose-6-phosphate (2-DG-6-P). Unlike glucose-6-phosphate, 2-DG-6-P cannot be further metabolized by phosphoglucose isomerase (PGI) or glucose-6-phosphate dehydrogenase. Consequently, it accumulates intracellularly, competitively inhibiting PGI and non-competitively inhibiting HK [2][8]. This catabolic block halts the production of downstream glycolytic intermediates (e.g., ATP, pyruvate, and precursors for nucleic acids and lipids), leading to severe energetic stress [3]. This ATP-depleting effect is significantly potentiated under hypoxic conditions, where cancer cells rely exclusively on glycolysis [2].
Interference with N-linked Glycosylation: Under normoxic conditions, 2-DG exerts toxicity primarily by interfering with protein glycosylation. Because glucose and mannose are C-2 epimers, 2-DG is structurally analogous to mannose. It is converted into 2-DG-GDP, which competes with mannose-GDP, disrupting the assembly of lipid-linked oligosaccharides in the endoplasmic reticulum (ER) [2][3]. This leads to the accumulation of misfolded proteins, triggering ER stress and the unfolded protein response (UPR). The resulting stress activates AMP-activated protein kinase (AMPK), which inhibits the mTOR pathway and induces autophagy and apoptosis [2][4].
Oxidative Stress and Antioxidant Depletion: 2-DG-6-P cannot fully traverse the pentose phosphate pathway (PPP), a major source of NADPH. The blockade of the PPP depletes cellular NADPH, which is essential for regenerating reduced glutathione and thioredoxin [2][3]. By simultaneously reducing pyruvate (an H2O2 scavenger) and NADPH, 2-DG severely compromises the antioxidant defenses of cancer cells, leading to the accumulation of reactive oxygen species (ROS) and subsequent oxidative damage [2][3].
4. Structure-Activity Relationship (SAR)
Modifications to the 2-DG scaffold have been explored to enhance its glycolytic inhibition and pharmacokinetic properties.
Halogenation at C-2: Replacing the hydrogen at C-2 with halogens yields analogs like 2-fluoro-2-deoxy-D-glucose (2-FDG), 2-chloro-2-deoxy-D-glucose (2-CDG), and 2-bromo-2-deoxy-D-glucose (2-BDG). 2-FDG is a more potent inhibitor of HK and glycolysis than 2-DG because the fluorine atom is energetically and conformationally more similar to a hydroxyl group than a hydrogen atom is [2]. The glycolytic inhibitory potency decreases as the size of the halogen increases (F > Cl > Br). However, because 2-FDG is not structurally analogous to mannose, it does not interfere with N-linked glycosylation and is therefore less effective at killing cancer cells under normoxic conditions compared to 2-DG [2].
O-Acetylation: To overcome the poor drug-like properties of 2-DG, researchers developed WP1122 (3,6-di-O-acetyl-2-deoxy-D-glucose). The substitution of hydroxyl groups with acetoxy groups at C-3 and C-6 increases the molecule's lipophilicity, allowing it to cross the blood-brain barrier (BBB) and cellular membranes via passive diffusion rather than relying solely on GLUT transporters [2]. Once intracellular, esterases cleave the acetyl groups to release active 2-DG. This prodrug approach significantly increases tissue concentration and half-life compared to unmodified 2-DG [2][4].
5. Current Limitations
Despite its mechanistic promise, the clinical utility of 2-DG is hampered by several significant limitations:
- High Dose Requirements and Toxicity: To effectively outcompete physiological glucose, 2-DG must be administered at doses equal to or exceeding circulating glucose levels. In clinical trials, such high doses (ranging from 45 to 300 mg/kg) have been associated with dose-limiting toxicities, including insulin-induced hypoglycemic symptoms (sweating, flushing), fatigue, dizziness, muscle weakness, and cardiotoxicity [1][2][3]. Chronic ingestion in animal models has also been linked to cardiac vacuolization and increased mortality [7].
- Metabolic Flexibility of Tumors: Under normoxic conditions, many cancer cells exhibit metabolic plasticity and can shift from glycolysis to OXPHOS using alternative carbon sources (e.g., glutamine or fatty acids). This renders 2-DG monotherapy largely ineffective in well-oxygenated tumor regions [2][3].
- Poor Pharmacokinetics: 2-DG has a short half-life and is rapidly metabolized and cleared, making it difficult to achieve and sustain the therapeutic concentrations required in target tissues [4].
6. Future Perspectives
To harness the anticancer potential of 2-DG while mitigating its limitations, future research is pivoting toward combination strategies and advanced drug delivery systems:
Combination Therapies: Because 2-DG monotherapy is insufficient to eradicate metabolically flexible tumors, combining it with OXPHOS inhibitors (such as the biguanide metformin) represents a promising strategy. This dual-inhibition approach induces a catastrophic energy crisis by simultaneously blocking both major ATP-producing pathways [3]. Additionally, combining 2-DG with standard chemotherapeutics or radiotherapy continues to show potential in overcoming drug resistance and enhancing tumor immunogenicity [1][3].
Prodrugs and Glycoconjugation: The development of prodrugs like WP1122, currently in clinical trials, offers a viable solution to the pharmacokinetic shortcomings of 2-DG by enhancing bioavailability and tissue penetration [2][4]. Furthermore, glycoconjugation—covalently linking 2-DG to classical chemotherapeutic agents (e.g., paclitaxel)—is an emerging frontier. This strategy exploits the overexpression of GLUT transporters in cancer cells to selectively deliver cytotoxic payloads, thereby improving tumor specificity, reducing off-target toxicity, and overcoming the pharmacokinetic incompatibilities of administering two separate drugs [2].
